GPT and anemia (phenotype): Ninety-two percent of patients developed treatment-emergent adverse events (TEAEs), with the most common grade 1–2 events including diarrhea (33%), alanine aminotransferase (ALT) elevation (18%), aspartate aminotransferase (AST) elevation (18%), fatigue (18%), anemia (15%), pyrexia (15%), and nausea (15%).